InDex Pharmaceuticals will attend the ECCO 2023 congress
InDex Pharmaceuticals announced yesterday that the company will attend the annual congress of the European Crohn’s and Colitis Organisation (ECCO), March 1-4, 2023 in Copenhagen. ECCO is the largest forum for specialists in inflammatory bowel disease globally.
InDex Pharmaceuticals will be present at booth #C3-17 in the exhibition hall at the Bella Center. InDex’s team members will be available on site to provide information about cobitolimod and the ongoing phase III program CONCLUDE, which is evaluating the Toll-like receptor 9 agonist cobitolimod, as a potential novel treatment for moderate to severe left-sided ulcerative colitis. In addition, InDex’s team members will take the opportunity to meet investigators of the Induction 1 study of the CONCLUDE program to discuss study progress with the coordinating Investigator Professor Raja Atreya.
"ECCO is the largest forum for specialists in inflammatory bowel disease in the world and a very significant industry and healthcare professional event,” said Jenny Sundqvist, CEO of InDex Pharmaceuticals. “ECCO provides a great opportunity for the team to further interact with healthcare professionals, potential partners and relevant stakeholders to progress our lead drug candidate cobitolimod and the phase III program CONCLUDE.”
Disclaimer: HC Andersen Capital receives payment from InDex Pharmaceuticals for a DigitalIR/Corporate Visibility agreement. /Claus Thestrup kl. 11.15 d. 28/02-2023
InDex Pharmaceuticals Holding
InDex Pharmaceuticals er en farmaceutisk udviklingsvirksomhed med fokus på immunologiske sygdomme, hvor der er et stort udækket medicinsk behov for nye behandlingsmuligheder. Virksomhedens førende aktiv er lægemiddelkandidaten cobitolimod, som er i et sent stadium i klinisk udvikling til behandling af moderat til svær colitis ulcerosa - en invaliderende, kronisk betændelse i tyktarmen. InDex har også udviklet en platform af patentbeskyttede stoffer i opdagelsesstadiet, såkaldte DNA-baserede ImmunoModulatory Sequences (DIMS), med potentiale til at blive brugt til behandling af forskellige immunologiske sygdomme. InDex er baseret i Stockholm, Sverige. Selskabets aktier (ticker INDEX) handles på Nasdaq First North Growth Market Stockholm.
Read more on company page